NCT04021212

Unknown

Pituitary Adenoma and Serum Lipid

Shandong Provincial Hospital Source

Compare

Other study identifiers

Sponsor study identifier

20190712

Study Type

observational

Estimated enrollment

1,000

Locations

1 country

Sites

1

Timeline

Study Start

September 1, 2020

Actual (reported)

Primary Completion

June 2024

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

June 2024

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Brief Summary

Pituitary adenomas are usually benign monoclonal neoplasms caused by a mixture of pituicyte alterations together with a changed endocrine and paracrine regulatory milieu. Thus, it can cause serious health problems such as abnormal target organ function, pain, disability and even death. In clinical practice, we found many patients with pituitary adenomas are usually accompanied by hyperlipidemia, which is the main cause of cardiovascular diseases. However, it has been unclear if there is an association between pituitary adenomas and serum lipid profile. In the present study, we aim to focus on the patients with pituitary adenomas and their lipid profile before and after operation including first occurrence and recurrence.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Estimated enrollment: 1,000 participants
Study completion date: June 2024
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
July 15, 2019
Actual (reported)
First Posted
July 16, 2019
Actual (reported)
Study Start
September 1, 2020
Actual (reported)
Primary Completion
June 2024
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 2024
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated: May 11, 2022
Status Verified: May 2022
Last Update Submitted: May 10, 2022

Conditions

Pituitary Adenoma 1, Acth-Secreting

Keywords

PituitaryPituitary AdenomaSerum Lipid LevelsResectionRecurrence

Outcome Measures

Primary Outcomes (1)

Change in serum lipid levels
Measured at pre-operative and 6 months after operation

Study Arms (1)

Patients with pituitary adenomas resection

Patients suffers from pituitary adenomas and undergo transsphenoidal surgery for at least once

Eligibility Criteria

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Patients diagnosed with pituitary adenomas and underwent an endoscopic transsphenoidal approach at the Shandong Provincial Hospital affiliated with Shandong University. All adenomas were resected by transsphenoidal surgery and identified by histological diagnoses.

You may qualify if:

Patients diagnosed with pituitary adenomas

Sponsors & Collaborators

Shandong Provincial Hospital
Governmentlead

Study Sites (1)

Shandong Provincial Hospital

Jinan, Shandong, 250021, China

RECRUITING

Shanshan ShaoCONTACT86-531-68776094 shaoshanshan11@126.com

Biospecimen

Retention: SAMPLES WITH DNA

serum，plasma, whole blood

MeSH Terms

Conditions

Pituitary DiseasesPituitary NeoplasmsRecurrence

Condition Hierarchy (Ancestors)

Hypothalamic DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesEndocrine System DiseasesEndocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHypothalamic NeoplasmsSupratentorial NeoplasmsBrain NeoplasmsCentral Nervous System Neoplasms

Study Officials

Jiajun Zhao
Shandong Provincial Hospital
STUDY CHAIR

Central Study Contacts

Ling Gao

CONTACT

+86 53168776910 linggao@sdu.edu.cn

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER GOV
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal Investigator

Study Record Dates

First Submitted

July 15, 2019

First Posted

July 16, 2019

Study Start

September 1, 2020

Actual (reported)

Primary Completion

June 2024

Estimated (date passed)

All adenomas were resected by transsphenoidal surgery and identified by histological diagnoses.

You may not qualify if:

Missing vital data, such as age, gender, serum lipid profile, pathology reports;
Complications or conditions that affect pituitary status and lipid metabolism, such as pregnancy, malignant adenomas or severe hepatic or renal dysfunction and
Use of any medication that affects the pituitary or lipid metabolism, including statins, fibrates, thyroid hormones, anti-thyroid drugs, iodine, amiodarone, alemtuzumab, lithium, tyrosine kinase inhibitors, interferon, estrogens, androgens,glucocorticoids, nonsteroidal anti-inflammatory drugs, antiepileptic drugs, rifampicin, furosemide, heparin or β-adrenoceptor blockers in the past 3 months.

Contact the study team to confirm eligibility.

Nervous System Neoplasms

Disease Attributes

Pathologic Processes

Pathological Conditions, Signs and Symptoms

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

June 2024

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated

May 11, 2022

Record last verified: 2022-05

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT04021212
Data provider: ClinicalTrials.gov
Source updated: 2022-05-11
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:37:08 UTC

Locations

CN(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Patients with pituitary adenomas resection

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations